Truist Securities Reiterates Buy on Iovance Biotherapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $17.
September 15, 2023 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on Iovance Biotherapeutics and maintained a price target of $17.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Iovance Biotherapeutics. The maintained price target of $17 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100